Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Effector Therapeutics Inc (EFTR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2024: EFTR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $10
1 Year Target Price $10
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -78.85% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2024 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 0.00M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 2 | Beta 0.22 | 52 Weeks Range 0.00 - 0.17 | Updated Date 06/30/2025 |
52 Weeks Range 0.00 - 0.17 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -12.57 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -83.33% | Return on Equity (TTM) -946.56% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -5133589 | Price to Sales(TTM) 69.65 |
Enterprise Value -5133589 | Price to Sales(TTM) 69.65 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.41 | Shares Outstanding 4704410 | Shares Floating 4657224 |
Shares Outstanding 4704410 | Shares Floating 4657224 | ||
Percent Insiders 2.91 | Percent Institutions 3.5 |
Analyst Ratings
Rating 2 | Target Price 10 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Effector Therapeutics Inc
Company Overview
History and Background
Effector Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2012. It focuses on developing selective small molecule inhibitors of selective translation regulators (STRs) for the treatment of cancer. The company went public in 2015. Significant milestones include the development of tomivosertib and zotatifin, both targeting STRs.
Core Business Areas
- Drug Development: Effector Therapeutics focuses on discovering, developing, and commercializing innovative treatments for cancer patients who lack effective options. They primarily develop small molecule inhibitors targeting selective translation regulators (STRs).
Leadership and Structure
Steve Worland is the current President and CEO. The company has a typical organizational structure for a biopharmaceutical company, with departments focused on research, development, clinical trials, and business operations.
Top Products and Market Share
Key Offerings
- Tomivosertib: Tomivosertib is a MNK1/2 inhibitor in clinical development for various cancers, including NSCLC and bladder cancer. There is no current market share data available since it is still in development. Competitors include other companies developing targeted therapies and immunotherapies for the same indications. Competitors include Merck (Keytruda), Bristol Myers Squibb (Opdivo), and AstraZeneca (Tagrisso).
- Zotatifin: Zotatifin is a small molecule inhibitor of eIF4A. There is no current market share data available since it is still in development. Competitors include other companies developing targeted therapies for relapsed/refractory lymphomas. Competitors include MorphoSys and Xencor.
Market Dynamics
Industry Overview
The pharmaceutical industry, specifically oncology, is highly competitive and rapidly evolving. There is significant demand for innovative cancer therapies, driving intense research and development efforts.
Positioning
Effector Therapeutics is positioned as a company developing novel small molecule inhibitors targeting specific pathways in cancer cells. Its competitive advantage lies in its focus on selective translation regulators, a relatively underexplored area in oncology.
Total Addressable Market (TAM)
The TAM for oncology drugs is estimated to be in the hundreds of billions of dollars annually. Effector Therapeutics is positioned to capture a portion of this market by developing targeted therapies for specific cancer subtypes. The exact TAM they can target depends on the specific indications they pursue and the success of their clinical trials.
Upturn SWOT Analysis
Strengths
- Novel approach targeting selective translation regulators
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Currently no marketed products
Opportunities
- Potential for strategic partnerships
- Expansion into new cancer indications
- Positive clinical trial results leading to regulatory approval
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
Competitors and Market Share
Key Competitors
- MRK
- BMY
- AZN
Competitive Landscape
Effector Therapeutics faces intense competition from established pharmaceutical companies with greater financial resources and broader pipelines. However, its novel approach to targeting selective translation regulators provides a potential competitive advantage.
Growth Trajectory and Initiatives
Historical Growth: Effector Therapeutics' growth has been driven by the advancement of its clinical pipeline. The company has achieved milestones in clinical trials and secured financing to support its operations.
Future Projections: Future growth depends on the success of ongoing clinical trials and the potential for regulatory approval of its drug candidates. Analyst estimates vary widely, reflecting the uncertainty associated with drug development.
Recent Initiatives: Recent initiatives include advancing tomivosertib and zotatifin through clinical trials, exploring new indications, and seeking strategic partnerships.
Summary
Effector Therapeutics is a clinical-stage biopharmaceutical company with a focus on novel cancer therapies. Its strength lies in its unique approach to targeting selective translation regulators. However, it faces challenges related to limited financial resources and dependence on clinical trial success. The company's future depends on positive clinical trial results and strategic partnerships to advance its pipeline.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and is not financial advice. The information provided is for informational purposes only and should not be construed as a recommendation to buy or sell securities. Market share estimates are approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Effector Therapeutics Inc
Exchange NASDAQ | Headquaters Solana Beach, CA, United States | ||
IPO Launch date 2021-08-26 | CEO, President, Treasurer &Secretary, and Director Mr. Craig R. Jalbert CIRA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://effector.com |
Full time employees 14 | Website https://effector.com | ||
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. The company's lead product candidates comprise Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer; and Zotatifin, a small molecule inhibitor of eukaryotic initiation factor 4A (eIF4E), which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as completed Phase 2a open-label expansion cohort in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. The company has a research collaboration and license agreement with Pfizer Inc. to research and develop small molecules that target eIF4E; and collaboration agreement with the Dana-Farber Cancer Institute on a Phase 2 clinical trial, evaluating Zotatifin as combination treatment in ER+ endometrial cancer and in low grade serous ovarian cancer. eFFECTOR Therapeutics, Inc. was incorporated in 2012 and is headquartered in Solana Beach, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.